Analysts Expect PDS Biotechnology Corporation (NASDAQ:PDSB) to Post -$1.00 Earnings Per Share

Share on StockTwits

Analysts predict that PDS Biotechnology Corporation (NASDAQ:PDSB) will post ($1.00) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for PDS Biotechnology’s earnings. PDS Biotechnology posted earnings per share of ($0.40) in the same quarter last year, which would indicate a negative year over year growth rate of 150%. The company is scheduled to issue its next quarterly earnings results on Thursday, February 20th.

According to Zacks, analysts expect that PDS Biotechnology will report full-year earnings of ($1.59) per share for the current financial year. For the next fiscal year, analysts forecast that the business will report earnings of ($1.59) per share. Zacks’ EPS averages are an average based on a survey of sell-side analysts that cover PDS Biotechnology.

A number of equities analysts have commented on PDSB shares. HC Wainwright initiated coverage on shares of PDS Biotechnology in a report on Tuesday, November 5th. They issued a “buy” rating and a $7.00 price objective on the stock. Chardan Capital reissued a “buy” rating and issued a $10.00 target price on shares of PDS Biotechnology in a research report on Monday, December 23rd.

Shares of PDSB traded down $0.06 during mid-day trading on Friday, reaching $1.31. The company had a trading volume of 207,400 shares, compared to its average volume of 108,026. The firm has a market capitalization of $7.92 million, a PE ratio of -0.55 and a beta of 2.31. The company’s fifty day simple moving average is $2.36. PDS Biotechnology has a fifty-two week low of $1.29 and a fifty-two week high of $11.80.

A number of institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC boosted its stake in PDS Biotechnology by 31.3% during the 4th quarter. Renaissance Technologies LLC now owns 120,269 shares of the company’s stock valued at $319,000 after purchasing an additional 28,700 shares during the period. Andesa Financial Management Inc. acquired a new stake in shares of PDS Biotechnology in the 4th quarter worth approximately $44,000. Finally, Amussen Hunsaker Associates LLC acquired a new stake in shares of PDS Biotechnology in the 3rd quarter worth approximately $49,000. 9.07% of the stock is owned by hedge funds and other institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical stage immuno-oncology company, develops multifunctional immunotherapeutic products. The company develops products to treat early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers.

Featured Story: Price to Earnings Ratio (PE) Basics

Get a free copy of the Zacks research report on PDS Biotechnology (PDSB)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with's FREE daily email newsletter.